Besides that, despite our in vitro assays showed that AT-II positively influenced anti-NAFLD effects and activated SERCA2 signaling through its FXR agonism, we could not exclude potential off-target effects in vivo due to the absence of experiments using FXR knockout mice. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.